Consider Steglatro as Another Flozin for Type 2 Diabetes
Steglatro (steh-GLAH-troh, ertugliflozin) will be the fourth SGLT2 inhibitor for type 2 diabetes in Canada.
Steglatro will join the other "flozins"...Invokana (canagliflozin), Forxiga (dapagliflozin), and Jardiance (empagliflozin).
All flozins lower A1C by about 0.4% to 0.7% and help patients lose about 2 to 3 kg of weight. But it's too soon to say if Steglatro has the CV benefits seen with Jardiance or Invokana.